User login
Key clinical point: Bone metastasis (BM) negatively affects survival in patients with colorectal cancer (CRC); however, triplet therapy (FOLFOXIRI)+bevacizumab maintained its survival advantage over doublet therapy (FOLFIRI/FOLFOX)+bevacizumab even in this prognostically unfavorable group.
Major finding: Overall, patients with vs without bone involvement at baseline reported shorter progression-free survival (PFS; hazard ratio [HR] 1.96; P < .001) and overall survival (OS; HR 2.04; P < .001), with survival after progression being poor among patients with vs without BM at the time of progression (HR 1.48; P = .002). The triplet+bevacizumab vs doublet+bevacizumab regimen provided survival advantage even in the presence of BM (PFS: HR 0.76; P < .001).
Study details: The data come from a pooled analysis of the TRIBE1 and TRIBE2 trials including 1187 patients with initially unresectable and previously untreated mCRC who received doublet or triplet chemotherapy plus bevacizumab.
Disclosures: No funding source was declared. Some authors declared serving as consultants, advisors, on speaker’s bureaus, or receiving research support from various sources.
Source: Dell'Aquila E et al. Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: A subanalysis of the TRIBE and TRIBE2 trials. ESMO Open. 2022;7(6):100606 (Oct 31). Doi: 10.1016/j.esmoop.2022.100606
Key clinical point: Bone metastasis (BM) negatively affects survival in patients with colorectal cancer (CRC); however, triplet therapy (FOLFOXIRI)+bevacizumab maintained its survival advantage over doublet therapy (FOLFIRI/FOLFOX)+bevacizumab even in this prognostically unfavorable group.
Major finding: Overall, patients with vs without bone involvement at baseline reported shorter progression-free survival (PFS; hazard ratio [HR] 1.96; P < .001) and overall survival (OS; HR 2.04; P < .001), with survival after progression being poor among patients with vs without BM at the time of progression (HR 1.48; P = .002). The triplet+bevacizumab vs doublet+bevacizumab regimen provided survival advantage even in the presence of BM (PFS: HR 0.76; P < .001).
Study details: The data come from a pooled analysis of the TRIBE1 and TRIBE2 trials including 1187 patients with initially unresectable and previously untreated mCRC who received doublet or triplet chemotherapy plus bevacizumab.
Disclosures: No funding source was declared. Some authors declared serving as consultants, advisors, on speaker’s bureaus, or receiving research support from various sources.
Source: Dell'Aquila E et al. Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: A subanalysis of the TRIBE and TRIBE2 trials. ESMO Open. 2022;7(6):100606 (Oct 31). Doi: 10.1016/j.esmoop.2022.100606
Key clinical point: Bone metastasis (BM) negatively affects survival in patients with colorectal cancer (CRC); however, triplet therapy (FOLFOXIRI)+bevacizumab maintained its survival advantage over doublet therapy (FOLFIRI/FOLFOX)+bevacizumab even in this prognostically unfavorable group.
Major finding: Overall, patients with vs without bone involvement at baseline reported shorter progression-free survival (PFS; hazard ratio [HR] 1.96; P < .001) and overall survival (OS; HR 2.04; P < .001), with survival after progression being poor among patients with vs without BM at the time of progression (HR 1.48; P = .002). The triplet+bevacizumab vs doublet+bevacizumab regimen provided survival advantage even in the presence of BM (PFS: HR 0.76; P < .001).
Study details: The data come from a pooled analysis of the TRIBE1 and TRIBE2 trials including 1187 patients with initially unresectable and previously untreated mCRC who received doublet or triplet chemotherapy plus bevacizumab.
Disclosures: No funding source was declared. Some authors declared serving as consultants, advisors, on speaker’s bureaus, or receiving research support from various sources.
Source: Dell'Aquila E et al. Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: A subanalysis of the TRIBE and TRIBE2 trials. ESMO Open. 2022;7(6):100606 (Oct 31). Doi: 10.1016/j.esmoop.2022.100606